サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1540909

タンパク質治療市場レポート：製品、治療領域、機能、地域別、2024～2032年

Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
タンパク質治療市場レポート：製品、治療領域、機能、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のタンパク質治療市場規模は2023年に3,456億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに6,035億米ドルに達し、2024～2032年の間に6.2％の成長率（CAGR）を示すと予測しています。がん、糖尿病、心血管疾患、自己免疫疾患などの慢性疾患の有病率の増加、タンパク質工学の急速な技術進歩、バイオ医薬品産業の拡大、多様な治療領域における製品の広範な応用は、市場を推進しているいくつかの要因です。

タンパク質治療は、病気の予防、管理、治療のためにタンパク質やペプチドを利用する治療法の一種です。これらの治療は、体内の特定の分子や経路を標的とするように設計されており、高度に的を絞った治療アプローチを記載しています。がん、自己免疫疾患、遺伝病など、幅広い疾患に対する革新的な解決策を記載しています。治療用蛋白質は天然由来のものから、あるいは組み換えDNA技術によって製造されたものまであり、非常に特異的で強力な治療法の開発を可能にしています。これらの治療用タンパク質は、モノクローナル抗体、成長因子、酵素、サイトカインなど様々な形態をとることができます。それらは体内の特定のレセプターや分子と相互作用し、細胞プロセスを調節したり、免疫反応を抑制・刺激したり、病気の原因物質を直接標的にしたりします。タンパク質治療の利点は、その高い特異性、効力、低毒性にあります。従来の低分子医薬品に比べ、有効性が向上し、副作用が少ないことが多いです。タンパク質治療は、様々な疾患において新たな治療選択肢を提供し、患者の転帰を改善することで、医療セグメントを大きく発展させてきました。

世界市場を大きく牽引しているのは、個別化医療への注目の高まりです。これに伴い、研究開発活動の活発化と医療インフラの拡大が市場に大きく寄与しています。さらに、製造プロセスの進歩が市場を活性化すると予想されます。これとは別に、遺伝子工学、タンパク質合成、生産技術における画期的な進歩は、タンパク質治療の効率性と有効性を高め、市場にプラスの影響を与えています。さらに、がん、糖尿病、心血管障害、自己免疫疾患などの慢性疾患の有病率の増加が市場を活性化しています。さらに、腫瘍学におけるタンパク質治療の広範な応用が市場を刺激しています。さらに、ドラッグデリバリーシステムの急速な技術革新により、タンパク質治療の送達が改善され、その有効性と患者のコンプライアンスが向上しています。徐放性製剤、ナノ粒子、標的ドラッグデリバリーシステムなどの新しいデリバリー方法は、タンパク質医薬品の治療可能性を高めることで市場の成長を促進しています。

タンパク質治療市場傾向/促進要因：

バイオ医薬品研究開発投資の拡大

バイオ医薬品企業や研究機関は、その特異性、有効性、標的性の高さから、タンパク質ベースの医薬品開発にますます注力するようになっています。バイオ医薬品セクターにおける研究開発投資の増加は、タンパク質治療の進歩に拍車をかけています。これらの投資は、タンパク質工学、創薬、製剤最適化に関する研究活動を支援し、新規かつ改良されたタンパク質治療の開発につながります。さらに、研究開発に充てられる多額の資金により、研究者は新たな治療標的を探索し、活性を高めるためにタンパク質構造を最適化し、大規模な前臨床試験や臨床試験を実施することができます。こうした努力は、様々な疾患に対する革新的な治療を導入することで市場の拡大に貢献しています。さらに、研究開発投資の拡大により、タンパク質治療の生産プロセスのスケールアップが促進され、より利用しやすく費用対効果の高いものとなっています。これにより、タンパク質ベースの医薬品の商業化と市場浸透が進みます。

バイオシミラーの拡大

バイオシミラー市場の拡大は市場に大きく貢献しています。バイオシミラーとは、承認された参照タンパク質治療と類似性の高い生物製剤のことです。いくつかの大ヒット生物製剤の特許が切れるにつれて、バイオシミラー市場は急速に拡大しています。バイオシミラーが利用可能になると、高価なタンパク質治療に代わる費用対効果の高い代替品が提供され、患者や医療システムにとってより利用しやすくなります。この手頃な価格の増加は、必要な治療への患者のアクセスを向上させ、市場の成長を促進します。さらに、バイオシミラーの採用は市場競争を促進します。競争は価格の引き下げにつながり、市場の拡大を促すとともに、バイオシミラーメーカーや参照蛋白質治療メーカーに製品の革新と改良の機会をもたらします。さらに、バイオシミラーに関する規制の枠組みやガイドラインが確立され、合理化されたことで、バイオシミラーの開発と承認に明確な道筋が示されるようになりました。その結果、医療関係者の信頼が高まり、バイオシミラーの採用が増加しています。バイオシミラー市場が拡大するにつれ、タンパク質治療の研究開発努力がさらに刺激されます。メーカーはより高度で差別化されたバイオシミラーの開発に努め、市場に明るい展望をもたらしています。

高齢化人口の増加

高齢化人口の増加は、市場にプラスの影響を与えています。世界人口の高齢化に伴い、アルツハイマー病、パーキンソン病、黄斑変性症、骨粗鬆症など、加齢に関連する疾患や症状の有病率が高くなっています。タンパク質治療は、高齢化社会が直面するこれらの特定の健康課題に対処するために開発・利用されています。さらに、タンパク質治療は、加齢に関連した疾患に対する標的治療の選択肢を提供し、従来の治療法に比べて有効性の向上と副作用の軽減を実現します。特定の分子経路を標的とし、これらの疾患の根本的なメカニズムに対処することで、患者の転帰と生活の質を改善することができます。さらに、高齢化社会における製品需要の増加が、市場成長の原動力となっています。製薬会社や研究機関は、この層の特定のニーズを満たすため、新規タンパク質治療の開発に投資しています。さらに、高齢化人口の増加はタンパク質治療の市場を拡大させ、メーカーに製品ポートフォリオの拡大と増産を促しています。その結果、タンパク質治療の入手可能性が広がり、市場の成長がさらに促進されることになります。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のタンパク質治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • モノクローナル抗体（mAbs）
  • ヒトインスリン
  • エリスロポエチン
  • 凝固因子
  • 融合タンパク質
  • その他

第7章 市場内訳：治療領域別

  • 代謝障害
  • 免疫疾患
  • 血液疾患
  • がん
  • ホルモン障害
  • 遺伝性疾患
  • その他

第8章 市場内訳：機能別

  • 酵素と調節活性
  • 特別標的活性
  • ワクチン
  • タンパク質診断

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Abbott Laboratories
    • Abbvie Inc.
    • Baxter International Inc.
    • Biogen Inc.
    • Csl Behring L.L.C.（CSL Limited）
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S（Novo Holdings A/S）
    • Pfizer Inc.
図表

List of Figures

  • Figure 1: Global: Protein Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Protein Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Protein Therapeutics Market: Breakup by Product (in %), 2023
  • Figure 4: Global: Protein Therapeutics Market: Breakup by Therapy Area (in %), 2023
  • Figure 5: Global: Protein Therapeutics Market: Breakup by Function (in %), 2023
  • Figure 6: Global: Protein Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Protein Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Protein Therapeutics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Protein Therapeutics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Protein Therapeutics (Human Insulin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Protein Therapeutics (Human Insulin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Protein Therapeutics (Erythropoietin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Protein Therapeutics (Erythropoietin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Protein Therapeutics (Clotting Factors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Protein Therapeutics (Clotting Factors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Protein Therapeutics (Fusion Protein) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Protein Therapeutics (Fusion Protein) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Protein Therapeutics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Protein Therapeutics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Protein Therapeutics (Metabolic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Protein Therapeutics (Metabolic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Protein Therapeutics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Protein Therapeutics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Protein Therapeutics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Protein Therapeutics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Protein Therapeutics (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Protein Therapeutics (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Protein Therapeutics (Hormonal Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Protein Therapeutics (Hormonal Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Protein Therapeutics (Genetic Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Protein Therapeutics (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Protein Therapeutics (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Protein Therapeutics (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Global: Protein Therapeutics (Enzymatic and Regulatory Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Global: Protein Therapeutics (Special Targeting Activity) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Global: Protein Therapeutics (Special Targeting Activity) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Global: Protein Therapeutics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Global: Protein Therapeutics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Global: Protein Therapeutics (Protein Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Global: Protein Therapeutics (Protein Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: North America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: North America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: United States: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: United States: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Canada: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Canada: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Asia Pacific: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Asia Pacific: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: China: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: China: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Japan: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Japan: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: India: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: India: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: South Korea: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: South Korea: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Australia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Australia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Indonesia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Indonesia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Europe: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Europe: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Germany: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Germany: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: France: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: France: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: United Kingdom: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: United Kingdom: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Italy: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Italy: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Spain: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Spain: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Russia: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Russia: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Latin America: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Latin America: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Brazil: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 83: Brazil: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 84: Mexico: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 85: Mexico: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Others: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 87: Others: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Middle East and Africa: Protein Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 89: Middle East and Africa: Protein Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 90: Middle East and Africa: Protein Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 91: Global: Protein Therapeutics Industry: SWOT Analysis
  • Figure 92: Global: Protein Therapeutics Industry: Value Chain Analysis
  • Figure 93: Global: Protein Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Protein Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Protein Therapeutics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Protein Therapeutics Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
  • Table 4: Global: Protein Therapeutics Market Forecast: Breakup by Function (in Million US$), 2024-2032
  • Table 5: Global: Protein Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Protein Therapeutics Market Structure
  • Table 7: Global: Protein Therapeutics Market: Key Players
目次
Product Code: SR112024A2431

The global protein therapeutics market size reached US$ 345.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 603.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032. The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders, the rapid technological advancements in protein engineering, the expanding biopharmaceutical industry, and the widespread product applications in diverse therapeutic areas are some factors propelling the market.

Protein therapeutics is a class of medical treatments utilizing proteins or peptides to prevent, manage, or cure diseases. These therapeutics are designed to target specific molecules or pathways within the body, providing a highly targeted approach to treatment. They offer innovative solutions for a wide range of conditions, including cancer, autoimmune disorders, genetic diseases, and more. They can be derived from natural sources or produced through recombinant DNA technology, allowing for the development of highly specific and potent therapies. These therapeutic proteins can take various forms, including monoclonal antibodies, growth factors, enzymes, and cytokines. They interact with specific receptors or molecules in the body, modulating cellular processes, inhibiting or stimulating immune responses, or directly targeting disease-causing agents. The advantages of protein therapeutics lie in their high specificity, potency, and low toxicity. They often offer improved efficacy and fewer side effects than traditional small-molecule drugs. They have significantly advanced the field of medicine, providing novel treatment options and improving patient outcomes across various diseases.

The global market is majorly driven by the increasing focus on personalized medicine. In line with this, the rising research and development activities and the expanding healthcare infrastructure are significantly contributing to the market. Furthermore, the advancements in manufacturing processes are expected to fuel the market. Apart from this, the breakthroughs in genetic engineering, protein synthesis, and production technologies have enhanced the efficiency and effectiveness of protein therapeutics, positively influencing the market. Moreover, the growing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is catalyzing the market. Besides, the widespread applications of protein therapeutics in oncology are stimulating the market. Additionally, the rapid innovations in drug delivery systems have improved the delivery of protein therapeutics, enhancing their efficacy and patient compliance. Novel delivery methods such as sustained-release formulations, nanoparticles, and targeted drug delivery systems are driving the market growth by increasing the therapeutic potential of protein drugs.

Protein Therapeutics Market Trends/Drivers:

Growing biopharmaceutical research and development investments

Biopharmaceutical companies and research institutions are increasingly focusing on the development of protein-based drugs due to their high specificity, efficacy, and targetability. The rise in R&D investments in the biopharmaceutical sector is fueling advancements in protein therapeutics. These investments support research activities related to protein engineering, drug discovery, and formulation optimization, leading to the development of novel and improved protein therapeutics. Furthermore, the substantial funds allocated to R&D enable researchers to explore new therapeutic targets, optimize protein structures for enhanced activity, and conduct extensive preclinical and clinical trials. These efforts contribute to the expansion of the market by introducing innovative treatments for various diseases. Moreover, the growing R&D investments facilitate the scaling-up of production processes for protein therapeutics, making them more accessible and cost-effective. This enables increased commercialization and market penetration of protein-based drugs.

Expansion of biosimilars

The expansion of the biosimilars market is significantly contributing to the market. Biosimilars are biologic drugs that are highly similar to approved reference protein therapeutics. As patents for several blockbuster biologics expire, the market for biosimilars is expanding rapidly. The availability of biosimilars provides cost-effective alternatives to expensive protein therapeutics, making them more accessible to patients and healthcare systems. This increased affordability enhances patient access to necessary treatments, driving market growth. Furthermore, the introduction of biosimilars fosters competition in the market. Competition leads to price reductions, encouraging market expansion and creating opportunities for biosimilar manufacturers and reference protein therapeutics companies to innovate and improve their products. Moreover, the regulatory frameworks and guidelines for biosimilars have become more established and streamlined, providing a clear pathway for their development and approval. This has instilled confidence in the healthcare community and resulted in increased biosimilar adoption. As the biosimilars market expands, it stimulates further research and development efforts in protein therapeutics. Manufacturers strive to develop more advanced and differentiated biosimilars, creating a positive outlook for the market.

Rising aging population

The rising aging population is positively influencing the market. As the global population ages, there is a higher prevalence of age-related diseases and conditions such as Alzheimer's disease, Parkinson's disease, macular degeneration, and osteoporosis. Protein therapeutics are being developed and utilized to address these specific health challenges the aging population faces. Furthermore, protein therapeutics offer targeted treatment options for age-related diseases, providing improved efficacy and reduced side effects as compared to traditional therapies. They can target specific molecular pathways and address the underlying mechanisms of these diseases, thereby improving patient outcomes and quality of life. Moreover, the increasing product demand among the aging population is driving market growth. Pharmaceutical companies and research institutions are investing in the development of novel protein therapeutics to meet the specific needs of this demographic. Additionally, the growing aging population creates a larger market for protein therapeutics, prompting manufacturers to expand their product portfolios and increase production. This, in turn, leads to a wider availability of protein therapeutics and further drives market growth.

Protein Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global protein therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, therapy area, and function.

Breakup by Product:

Monoclonal Antibodies (mAbs)

Human Insulin

Erythropoietin

Clotting Factors

Fusion Protein

Others

Monoclonal Antibodies (mAbs) dominates the market

The report has provided a detailed breakup and analysis of the market based on product. This includes monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. According to the report, monoclonal antibodies (mAbs) represented the largest segment.

Monoclonal antibodies (mAbs) are extensively used to treat cancer, autoimmune disorders, and inflammatory diseases. The increasing prevalence of these conditions, coupled with advancements in antibody engineering and production technologies, drives the demand for mAbs and contributes to the market growth.

On the other hand, human insulin is a vital protein therapeutic for managing diabetes. With the rising incidence of diabetes worldwide, the demand for insulin and insulin analogs is increasing, leading to market growth in this segment. Moreover, erythropoietin (EPO) is another important therapeutic protein stimulating red blood cell production. It is used to treat anemia, particularly in patients with chronic kidney disease and cancer undergoing chemotherapy. The expanding patient pool requiring EPO therapy is driving the growth of this segment.

Besides this, the clotting factors are proteins essential for blood clotting. They are used to manage bleeding disorders such as hemophilia. The growing awareness, diagnosis, and treatment of hemophilia fuel the demand for clotting factors and contribute to the market. In addition, fusion proteins, which combine two or more functional protein domains, have gained significant attention in the development of innovative therapeutics. They offer unique treatment approaches for various diseases, including cancer and autoimmune disorders, thus driving the market in this segment.

Breakup by Therapy Area:

Metabolic Disorders

Immunological Disorders

Hematological Disorders

Cancer

Hormonal Disorders

Genetic Disorders

Others

Metabolic Disorders holds the largest share of the market

A detailed breakup and analysis of the market based on the therapy area have also been provided in the report. This includes metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. According to the report, metabolic disorders accounted for the largest market share.

Metabolic disorders encompass conditions such as diabetes, obesity, and hypercholesterolemia. Protein therapeutics, such as insulin for diabetes management, are crucial in treating and controlling these disorders. The rising prevalence of metabolic disorders, coupled with the increasing demand for targeted and effective treatments, is driving the growth of the market in this segment.

On the contrary, immunological disorders, including autoimmune diseases and inflammatory conditions, represent another significant therapy area for protein therapeutics. Monoclonal antibodies and other protein-based drugs modulate the immune system and target specific disease pathways. The growing incidence of immunological disorders and the expanding range of approved protein therapeutics for these conditions are driving the market.

In addition, cancer remains one of the primary drivers of the market. Protein-based therapies, including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors, have revolutionized cancer treatment. The increasing incidence of cancer globally, coupled with the development of targeted therapies and immunotherapies, is propelling the growth of the market in oncology.

Breakup by Function:

Enzymatic and Regulatory Activity

Special Targeting Activity

Vaccines

Protein Diagnostics

A detailed breakup and analysis of the market based on the function have also been provided in the report. This includes enzymatic and regulatory activity, special targeting activity, vaccines, and protein diagnostics.

Protein therapeutics with enzymatic and regulatory activity are vital in modulating biological processes and metabolic pathways. These proteins act as enzymes, receptors, or signaling molecules, offering therapeutic benefits in various diseases. The development of novel protein therapeutics with specific enzymatic or regulatory functions drives market growth in this segment.

Furthermore, special targeting activity refers to protein therapeutics targeting certain cells, tissues, or molecular targets. Monoclonal antibodies and antibody-drug conjugates are examples of protein therapeutics with special targeting activity. They can precisely recognize and bind to specific molecules or cells, providing highly targeted therapies. The increasing demand for targeted treatments in conditions such as cancer and autoimmune diseases fuels the growth of protein therapeutics in this segment.

Moreover, vaccines are another significant segment in the market. Protein-based vaccines utilize specific proteins or peptides to stimulate an immune response and confer immunity against infectious diseases. The global focus on vaccination programs, the emergence of new infectious diseases, and the need for improved vaccine technologies drive market growth in this segment.

Besides, protein diagnostics involves using proteins or protein-based assays for diagnostic purposes. These diagnostics can detect specific proteins or biomarkers associated with diseases, aiding in early detection, disease monitoring, and personalized treatment. The growing demand for accurate and reliable diagnostic tools fuels the growth of protein diagnostics and contributes to the overall market.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest protein therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

North America, particularly the United States, holds a significant market share. The region benefits from advanced healthcare infrastructure, a strong presence of biopharmaceutical companies, and robust research and development activities. The presence of key players and extensive investments in protein therapeutics research contribute to market growth in North America. Additionally, the high prevalence of chronic diseases, a large aging population, and favorable reimbursement policies further drive the market in the region.

On the other hand, Asia Pacific is emerging as a rapidly growing market. The region has a large population base, increasing healthcare expenditure, and a rising prevalence of chronic diseases. Countries such as China, Japan, and India are witnessing substantial growth in the biopharmaceutical industry and investing in research and development. Moreover, the increasing awareness of personalized medicine and growing demand for cost-effective treatment options are driving the adoption of protein therapeutics in Asia Pacific.

Competitive Landscape:

Top companies are investing heavily in scientific research to identify new therapeutic targets and develop protein-based drugs with enhanced efficacy and safety profiles. They leverage their protein engineering, molecular biology, and biotechnology expertise to design and optimize therapeutic proteins. Furthermore, these companies establish strategic collaborations with academic institutions, research organizations, and other pharmaceutical companies to access new technologies, expand their pipelines, and accelerate development. Collaborations enable the exchange of knowledge, resources, and expertise, fostering innovation and driving the market. Moreover, successful commercialization strategies play a vital role in driving market growth. These companies employ robust marketing and sales efforts to promote and distribute their products to healthcare providers and patients worldwide. They conduct extensive clinical trials, generate compelling clinical data, and obtain regulatory approvals to ensure market access. Additionally, the top companies continuously invest in manufacturing capabilities and quality control systems to meet the growing demand and ensure a consistent supply of their products. This commitment to manufacturing excellence helps them meet the needs of patients, healthcare providers, and payers, further driving the market growth.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Amgen Inc.

Abbott Laboratories

Abbvie Inc.

Baxter International Inc.

Biogen Inc.

Csl Behring L.L.C. (CSL Limited)

Eli Lilly and Company

F. Hoffmann-La Roche AG (Roche Holding AG)

Johnson & Johnson

Merck & Co. Inc.

Novo Nordisk A/S (Novo Holdings A/S)

Pfizer Inc.

Recent Developments:

In 2020, Amgen Inc. entered into a collaboration with Adaptive Biotechnologies to develop and commercialize fully human-neutralizing antibodies targeting SARS-CoV-2, the virus that causes COVID-19.

In 2021, Abbott Laboratories received FDA clearance for their Tendyne Transcatheter Mitral Valve Replacement (TMVR) system, a minimally invasive therapy for patients with severe mitral regurgitation.

In 2020, AbbVie Inc. acquired Allergan, a pharmaceutical company known for its portfolio of aesthetic and therapeutic products, including Botox.

Key Questions Answered in This Report

  • 1. What was the size of the global protein therapeutics market in 2023?
  • 2. What is the expected growth rate of the global protein therapeutics market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global protein therapeutics market?
  • 4. What are the key factors driving the global protein therapeutics market?
  • 5. What is the breakup of the global protein therapeutics market based on the product?
  • 6. What is the breakup of the global protein therapeutics market based on the therapy area?
  • 7. What are the key regions in the global protein therapeutics market?
  • 8. Who are the key players/companies in the global protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Protein Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Human Insulin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Erythropoietin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Clotting Factors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Fusion Protein
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Immunological Disorders
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hematological Disorders
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Hormonal Disorders
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Genetic Disorders
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Special Targeting Activity
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Vaccines
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Protein Diagnostics
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Abbott Laboratories
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Abbvie Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Baxter International Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Biogen Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Csl Behring L.L.C. (CSL Limited)
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 SWOT Analysis
    • 14.3.9 Johnson & Johnson
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck & Co. Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novo Nordisk A/S (Novo Holdings A/S)
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis